

# **Keratoconjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/K4A0F6CA059EEN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: K4A0F6CA059EEN

## **Abstracts**

The 7 major keratoconjunctivitis markets are expected to exhibit a CAGR of 4.03% during 2024-2034.

The keratoconjunctivitis market has been comprehensively analyzed in IMARC's new report titled "Keratoconjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Keratoconjunctivitis is a medical term that refers to the inflammation of the cornea and conjunctiva, the clear tissues covering the front of the eye and the inside of the eyelids, respectively. It can be a serious condition, potentially leading to vision loss. The symptoms of this illness can vary based on the severity and cause of the disease. Some common indications of the ailment include redness of the eye, pain or discomfort, photophobia, excessive tearing or watery eyes, blurred or hazy vision, a foreign body sensation in the eye, discharge from the eyes, etc. The diagnosis of keratoconjunctivitis is mainly made on the basis of the patient's medical history, clinical features, and a comprehensive eye examination. The healthcare provider will conduct viral cultures or polymerase chain reaction (PCR) tests to identify the specific pathogen responsible for the infection. Additionally, numerous special studies, such as tear breakup time or Schirmer's test, may be performed to quantify tear production and stability in patients. In certain severe or atypical cases, a tissue biopsy is utilized for laboratory analysis and to rule out other underlying causes of the disease.

The increasing prevalence of eye disorders, like blepharitis and meibomian gland dysfunction, which can lead to inadequate production of the oily layer of tears, causing them to evaporate faster, is primarily driving the keratoconjunctivitis market. In addition to this, the rising incidences of exposure to dry or windy climates, air conditioning, and

heating systems that can cause discomfort in the eyes are also creating a positive outlook for the market. Moreover, the widespread adoption of artificial tears to aid in the healing process of the cornea and conjunctiva by keeping the ocular surface moist and supporting the repair of damaged tissues is further bolstering the market growth. Apart from this, the inflating application of topical steroids, since they suppress the inflammatory response in the eye to minimize redness, swelling, and discomfort associated with the condition, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of punctal plugs, which are tiny devices inserted into the tear ducts of the eyes to retain moisture on the eye's surface, is expected to drive the keratoconjunctivitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the keratoconjunctivitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for keratoconjunctivitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the keratoconjunctivitis market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

## Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the keratoconjunctivitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the keratoconjunctivitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current keratoconjunctivitis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

#### Market Insights

How has the keratoconjunctivitis market performed so far and how will it perform in the coming years?

What are the market shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the keratoconjunctivitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the keratoconjunctivitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of keratoconjunctivitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of keratoconjunctivitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of keratoconjunctivitis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with keratoconjunctivitis across the seven major markets?

What is the size of the keratoconjunctivitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of keratoconjunctivitis?

What will be the growth rate of patients across the seven major markets?

### Keratoconjunctivitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for keratoconjunctivitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the keratoconjunctivitis market?

What are the key regulatory events related to the keratoconjunctivitis market?

What is the structure of clinical trial landscape by status related to the keratoconjunctivitis market?

What is the structure of clinical trial landscape by phase related to the keratoconjunctivitis market?

What is the structure of clinical trial landscape by route of administration related to the keratoconjunctivitis market?

## Contents

?1 Preface

## 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

## 3 EXECUTIVE SUMMARY

## 4 KERATOCONJUNCTIVITIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

## 5 KERATOCONJUNCTIVITIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

## 6 PATIENT JOURNEY

## 7 KERATOCONJUNCTIVITIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 KERATOCONJUNCTIVITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 KERATOCONJUNCTIVITIS - UNMET NEEDS**

## **10 KERATOCONJUNCTIVITIS - KEY ENDPOINTS OF TREATMENT**

## **11 KERATOCONJUNCTIVITIS - MARKETED PRODUCTS**

- 11.1 List of Keratoconjunctivitis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Verkazia (Ciclosporin ophthalmic) - Santen SAS
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.



## **12 KERATOCONJUNCTIVITIS - PIPELINE DRUGS**

### 12.1 List of Keratoconjunctivitis Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. KERATOCONJUNCTIVITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. KERATOCONJUNCTIVITIS – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 KERATOCONJUNCTIVITIS - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Keratoconjunctivitis - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Keratoconjunctivitis - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Keratoconjunctivitis - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Keratoconjunctivitis - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

- 15.3.3 Keratoconjunctivitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Keratoconjunctivitis - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Keratoconjunctivitis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Keratoconjunctivitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Keratoconjunctivitis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Keratoconjunctivitis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Keratoconjunctivitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Keratoconjunctivitis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Keratoconjunctivitis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Keratoconjunctivitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Keratoconjunctivitis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Keratoconjunctivitis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Keratoconjunctivitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Keratoconjunctivitis - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Keratoconjunctivitis - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)

- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Keratoconjunctivitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Keratoconjunctivitis - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Keratoconjunctivitis - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Keratoconjunctivitis - Access and Reimbursement Overview

## **16 KERATOCONJUNCTIVITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 KERATOCONJUNCTIVITIS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 KERATOCONJUNCTIVITIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Keratoconjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/K4A0F6CA059EEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/K4A0F6CA059EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

